Article, News
Prescient Therapeutics unveils novel adjuvant for enhancing cellular immunotherapy: CellPryme-A
CellPryme-A is the latest in a portfolio of platform cell technologies that can not only create innovative programs for Prescient, but are also enabling technologies…
News
Prescient Therapeutics to unveil CellPryme-A platform at CAR-TCR summit in Boston
Prescient Therapeutics Ltd (ASX:PTX) has been invited to present two sessions at the upcoming CAR-TCR Summit in Boston on September 19 to 22, during which the…
News
Prescient Therapeutics hails collaboration with MD Anderson Cancer Center for blood cancer therapy
Prescient Therapeutics Ltd (ASX:PTX) CEO and managing director Steven Yatomi-Clarke chats with Andrew Scott from Proactive about the company’s strategic collaboration agreement with the University of Texas MD…
Article, News
Prescient Therapeutics to collaborate with largest cancer centre in the US to develop blood cancer treatment
“We believe that OmniCAR is a transformational platform for cellular immunotherapy, and we look forward to testing the potential of this promising TCR-like binder for…
News
Prescient Therapeutics enters into OmniCAR cell production agreement with Q-Gen Cell
Q-Gen Cell will produce and deliver the OmniCAR cell lines from its Brisbane facility to be used for Prescient’s upcoming clinical trials.
News
The companies aiming to beat cancer serve up the highlights in the June quarter
Precedence Research suggests the global cancer therapeutics market size is predicted to surpass US$365.99 billion by 2030 and expand growth at a CAGR of 9.1%…
News
Challenging the pace of change in healthcare: Prescient Therapeutics
“The fact of the matter is there are people walking around now who shouldn’t be alive, but they are because of our trials, which is…
News
Prescient Therapeutics’ PTX-100 for peripheral T-cell lymphoma treatment granted US orphan drug status
The designation brings considerable benefits including guaranteed market exclusivity for seven years and a waiver of Prescription Drug User Fee Act fees for orphan drugs,…
News
Prescient Therapeutics granted key US patent for OmniCAR portfolio of therapies
Prescient Therapeutics Ltd (ASX:PTX) has been granted a US patent for its flagship OmniCAR portfolio entitled ‘SpyCatcher and SpyTag: Universal Immune Receptor for T Cells’ that…
News
FIVE at FIVE AU: Iron ore cops a belting and energy prices could stay high until 2025
All the major banks have now lifted interest rates in line with the Reserve Bank of Australia’s cash rate hike of 0.5% yesterday, however that…